Adjuvant endocrine therapy for premenopausal women with breast cancer: Patient adherence and physician prescribing practices in Mexico

被引:5
|
作者
Villarreal-Garza, Cynthia [1 ,2 ]
Mesa-Chavez, Fernanda [1 ,2 ]
Ferrigno, Ana S. [1 ,2 ]
Garza-Ramos, Cynthia De la [1 ,2 ]
Fonseca, Alan [2 ,3 ]
Villanueva-Tamez, Karen [1 ]
Campos-Salgado, Jose Y. [3 ]
Cruz-Ramos, Marlid [2 ,3 ]
Rodriguez-Gomez, David O. [1 ]
Ruiz-Cruz, Sandy [3 ]
Cabrera-Galeana, Paula [3 ]
机构
[1] Tecnol Monterrey, Hosp Zambrano Hell TecSalud, Breast Canc Ctr, Batallon San Patricio 112,14th Floor, San Pedro Garza Garcia 66278, Nuevo Leon, Mexico
[2] Joven & Fuerte Programa Atenc & Invest Mujeres Jo, Holbein 227,Int 210AB, Mexico City 03720, DF, Mexico
[3] Inst Nacl Cancerol, Dept Tumores Mamarios & Invest, San Fernando 22,Belisario Dominguez Secc 16, Mexico City 14080, DF, Mexico
来源
BREAST | 2021年 / 59卷
关键词
Breast cancer; Endocrine therapy; Adherence; Premenopausal; Prescribing practices; Mexico; CLINICAL-PRACTICE GUIDELINES; HORMONAL-THERAPY; EARLY DISCONTINUATION; OVARIAN SUPPRESSION; TAMOXIFEN; NONADHERENCE; COHORT; SURVIVORS; PERSPECTIVES; PERSISTENCE;
D O I
10.1016/j.breast.2021.05.013
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: In resource-constrained settings, data regarding breast cancer patients' adherence to endocrine therapy (ET) and physicians' prescribing practices is limited. This study aims to decrease this knowledge gap in a real-world clinical practice. Methods: Premenopausal women with stage 0-III hormone-sensitive breast cancer and receiving adjuvant ET during the past 1-5 years were identified in three Mexican referral centers. Participants' self reported ET compliance, clinicopathologic characteristics, ET-related knowledge and beliefs, experienced adverse effects, social support, and patient-physician relationships were evaluated. Physician ET prescribing practices were compared with the gold standard according to international and national guidelines to assess clinicians' adherence to standard-of-care prescription. Results: In total, 95/132 (72%) and 35/132 (27%) participants reported complete and acceptable adherence, respectively. Incomplete adherence was mainly attributed to forgetfulness, adverse effects, and unwillingness to take ET. Being employed/studying (p = 0.042), worrying about long-term ET use (p = 0.031), and experiencing >7 ET-related symptoms (p = 0.018) were associated with incomplete adherence. Guideline-endorsed regimens were prescribed in 84/132 (64%) patients, while the rest should have undergone ovarian function suppression (OFS) but instead received tamoxifen monotherapy. Conclusions: Premenopausal Mexican women self-report remarkably high rates of adequate ET adherence. However, a considerable proportion misses >1 doses/month, usually because of forgetfulness. Notably, only 64% receive standard-of-care ET due to suboptimal prescription of OFS. Interventions that remind patients to take their ET, refine physicians' knowledge on the importance of OFS in high-risk patients, and increase access to OFS could prove pivotal to enhance optimal ET implementation and adherence, which could translate into improved patient outcomes. (c) 2021 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
引用
收藏
页码:8 / 15
页数:8
相关论文
共 50 条
  • [1] Prescribing practices of endocrine therapy for premenopausal breast cancer patients in Mexico
    Villarreal-Garza, C.
    Mesa-Chavez, F.
    De la Garza-Ramos, C.
    Ferrigno, A. S.
    Villanueva-Tamez, K.
    Fonseca, A.
    Campos-Salgado, J. Y.
    Rodriguez-Gomez, D. O.
    Ruiz-Cruz, S.
    Cabrera-Galeana, P.
    Garcia-Garcia, M.
    Cruz-Ramos, M.
    BREAST, 2021, 56 : S19 - S20
  • [2] Social Characteristics and Adherence to Adjuvant Endocrine Therapy in Premenopausal Women With Breast Cancer
    Schmidt, Julie A.
    Woolpert, Kirsten M.
    Hjorth, Cathrine F.
    Farkas, Dora K.
    Ejlertsen, Bent
    Cronin-Fenton, Deirdre
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (28)
  • [3] Adjuvant endocrine therapy in premenopausal women with breast cancer
    Antonio González Martín
    Susana de la Cruz
    Raúl Márquez
    Breast Cancer Research and Treatment, 2010, 123 : 43 - 47
  • [4] Adjuvant endocrine therapy in premenopausal women with breast cancer
    Gonzalez Martin, Antonio
    de la Cruz, Susana
    Marquez, Raul
    BREAST CANCER RESEARCH AND TREATMENT, 2010, 123 : 43 - 47
  • [5] Adjuvant Endocrine Therapy in Premenopausal Women With Breast Cancer
    Kadakia, Kunal C.
    Henry, N. Lynn
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2015, 13 (10) : 663 - 672
  • [6] Adjuvant endocrine therapy for premenopausal women with breast cancer
    Puhalla, Shannon
    Brufsky, Adam
    Davidson, Nancy
    BREAST, 2009, 18 : S122 - S130
  • [7] Adjuvant endocrine therapy for premenopausal women with early breast cancer
    Ting Bao
    Nancy E Davidson
    Breast Cancer Research, 9
  • [8] Adjuvant endocrine therapy for premenopausal women with early breast cancer
    Bao, Ting
    Davidson, Nancy E.
    BREAST CANCER RESEARCH, 2007, 9 (06)
  • [9] Adjuvant endocrine therapy for premenopausal women with early breast cancer
    Dellapasqua, S
    Colleoni, M
    Gelber, RD
    Goldhirsch, A
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (08) : 1736 - 1750
  • [10] Adjuvant Endocrine Therapy in Breast Cancer: Evolving Paradigms in Premenopausal Women
    Lorenzo Rossi
    Olivia Pagani
    Current Treatment Options in Oncology, 2017, 18